Dupuytren’s Contracture

Injectable Collagenase Clostridium Histolyticum: A New Nonsurgical Treatment for Dupuytren’s Disease

Gilpin D, Coleman S, Hall S, et al (Brisbane Hand and Upper Limb Clinic, Queensland; Rivercity Private Hosp, Auchenflower, Queensland; Emeritus Res, Malvern, Victoria, Australia; et al) J Hand Surg 35A:2027-2038, 2010^§

Abstract

Purpose

The Collagenase Option for the Reduction of Dupuytren’s (CORD) II study investigated the efficacy and safety of injectable Xiaflex (collagenase clostridium histolyticum), in patients with Dupuytren’s contracture.

Methods

This was a prospective, randomized, placebo-controlled trial with 90-day double-blind and 9-month open-label phases. We randomized patients with contractures affecting metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joints 2 to 1 to collagenase (0.58 mg) or placebo. Cords received a maximum of 3 injections. Cord disruption was attempted the day after injection using a standardized finger extension procedure. Primary end point was reduction in contracture to 0° to 5° of normal 30 days after the last injection.

Results

Only gold members can continue reading. Log In or Register to continue

Share this:

• X
• Facebook

Related

Related posts:

Systematic Review of Conservative Interventions for Osteoarthritis of the Hand of Open Trigger Finger Release of Early Postoperative Pain and the Effectiveness of Perifracture Site Injections Following Volar Plating for Distal Radius Fractures of Arthrolysis by Lateral and Medial Approaches and Hinged External Fixation in the Treatment of Stiff Elbow Progression of Asymptomatic Rotator Cuff Tears: A Prospective Study of Clinical and Sonographic Variables 35

Stay updated, free articles. Join our Telegram channel

Join